ERBB2 and breast cancer: Hyperglycemia and diarrhea were the most commonly reported serious adverse events.<h4>Conclusion</h4>PI3Kα inhibitors show promising efficacy in PIK3CA-mutated HR+/HER2- breast cancer, but publication bias, resistance, target-specific toxicity, and geographic disparities remain major barriers.